prime medicine(US:PRME)2026-03-03 13:02Financial Performance - Prime Medicine reported total revenue of $4.632 million for the year ended December 31, 2025, compared to $2.983 million in 2024, representing a 55.2% increase[21]. - The net loss for 2025 was $201.1 million, compared to a net loss of $195.9 million in 2024, reflecting a 2.3% increase in losses[11]. - As of December 31, 2025, Prime Medicine had cash, cash equivalents, investments, and restricted cash totaling $191.4 million, down from $204.5 million in 2024[11]. Research and Development - Research and development (R&D) expenses increased to $160.6 million in 2025 from $155.3 million in 2024, driven primarily by license and intellectual property costs[11]. - The company anticipates generating preclinical proof of concept data for its Cystic Fibrosis program in 2026, supported by the Cystic Fibrosis Foundation[5]. Administrative Expenses - General and administrative (G&A) expenses rose to $52.3 million in 2025, up from $50.2 million in 2024, attributed to higher professional and consultant fees[11]. Regulatory and Clinical Developments - Prime Medicine plans to submit an investigational new drug (IND) application for its Wilson Disease program in the first half of 2026 and for its Alpha-1 Antitrypsin Deficiency program in mid-2026[3]. - Initial clinical data for both the Wilson Disease and Alpha-1 Antitrypsin Deficiency programs is expected in 2027[3]. - The company is actively engaging with the FDA regarding PM359 for Chronic Granulomatous Disease (CGD) and plans to submit a Biologics License Application (BLA) following final alignment[11]. - Prime Medicine's Phase 1/2 study of PM359 showed rapid neutrophil and platelet engraftment, with durable restoration of NADPH oxidase activity and early clinical benefits[11].